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Dementia is caused by a variety of neurodegenerative disease(s) and is associated with a 29 
decline in memory and other cognitive abilities, while inflicting enormous socioeconomic 30 
burden. The complexity of dementia and its associated comorbidities, present immense 31 
challenges for dementia research and care, particularly in clinical decision-making.  32 
Main Body 33 
Despite lack of disease modifying therapies, there is an increasing and urgent need to make 34 
timely and accurate clinical decisions in dementia diagnosis and prognosis to allow 35 
appropriate care and treatment. However, the dementia care pathway is currently suboptimal. 36 
We propose that through computational approaches, understanding of dementia aetiology 37 
could be improved, and dementia assessments could be more standardised, objective and 38 
efficient. In particular, we suggest that these will involve appropriate data infrastructure, the 39 
use of data-driven Computational Neurology approaches, and the development of practical 40 
clinical decision support systems. We also discuss the technical, structural, economic, political 41 
and policy-making challenges that accompany such implementations.  42 
Conclusion 43 
The data-driven era for dementia research has arrived with the potential to transform the 44 
healthcare system, creating a more efficient, transparent and personalised service for 45 
dementia.  46 
 47 
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Background  53 
 54 
Dementia refers to a clinical syndrome distinct from physiological ageing, caused by one or 55 
more pathological processes, and characterised by progressive impairment in cognition and 56 
everyday functioning [1]. Alzheimer’s disease (AD), typically characterised by impairment in 57 
memory, is the most common subtype of dementia, constituting 60-70% of the cases [1]. AD 58 
can be categorised as familial AD (with family history of the disease and early AD onset) and 59 
sporadic AD, with the latter overwhelmingly being the most common type [2]. AD may co-exist 60 
with pathological processes characteristic of other common dementia subtype such as 61 
vascular dementia, frontotemporal dementia, and Lewy body dementia [1]. Further, there may 62 
also be co-morbidities with other illnesses such as epilepsy [3]. To add to the complexity, the 63 
prodromal stages, or mild cognitive impairment (MCI), associated with some dementia 64 
subtypes, can be loosely defined and heterogenous, particularly when assessments are 65 
subject to factors like delirium, psychiatric illness and the effects of medication [4, 1].  66 
 67 
Globally, it is estimated that there were 47 million people with dementia in 2015, and with a 68 
rapidly growing ageing population, this is expected to reach 75 million by 2030, and 132 million 69 
by 2050 [5]. Dementia has a considerable impact on the wellbeing and functioning of those 70 
living with the disease, but also on their families and caregivers. Dementia care can place 71 
health and social care services under operational and financial strain, costing an estimated 72 
US$ 818 billion in 2015 and estimated US$2 trillion in 2030 [5]. In the UK, dementia costs £26 73 
billion per year. In 2014, 850,000 people in the UK were estimated to be living with dementia, 74 
and this may rise to 1.6 million by 2040 [6]. In neighbouring Ireland, there were about 48,000 75 
people with dementia in 2011 and this is projected to increase to 132,000 by 2041, while 76 
costing €1.7 billion annually, [7, 8].  77 
 78 
Despite the demand for dementia care and treatment, to date, there are no disease modifying 79 
therapies for the most common dementia subtypes. Medications that target particular 80 
neurotransmitter systems (e.g. cholinesterase inhibitors) and nutritional supplements have 81 
been proposed to slow the early cognitive decline associated with mild to moderate AD and 82 
Lewy body dementia [9, 10]. Trials investigating disease modifying therapies have mostly 83 
targeted the formation of beta-amyloid plaques, suggested to be one of the neuropathological 84 
hallmarks of AD, but the results have so far been underwhelming [11, 12]. This may be 85 
attributed to testing people with dementia too late; by the time that the clinical symptoms have 86 
manifested themselves, amyloid may have been accumulating in brain structures for several 87 
years [13, 14]. Therapies targeting hyperphosphorylated tau (twisted fibres of tau proteins), 88 
the other main neuropathological substrate of AD, have also failed to demonstrate significant 89 
improvements in clinical outcomes [13, 14]. In all likelihood, AD and other dementia subtypes 90 
are likely to be the product of interactions between multiple factors, including, but not limited 91 
to cholinergic neuronal damage, neuroinflammation, oxidative stress, glucose 92 
hypometabolism, and more recently, gut microbiome perturbations via the immune system, 93 
endocrine system, vagus nerve, and bacteria-derived metabolites [14]. It is also possible that 94 
some of these hypotheses could be related [15] but further confirmatory work is required.  95 
 96 
Regardless of our incomplete understanding of dementia, the rising global population and 97 
longer average lifespan [16, 1] make an increasing and urgent case for timely and accurate 98 
recognition of dementia and its subtypes, particularly in guiding clinical decision regarding 99 
appropriate clinical care. Indeed, it is projected that the direct healthcare costs of early 100 
diagnosis may be offset by the cost savings arising from the earlier targeting of patients to the 101 
appropriate clinical care pathways [17]. Such savings may be linked to the benefits of earlier 102 
delivery of dementia medication and caregiver interventions, and delaying institutionalisation, 103 
thereby reducing the overall direct and indirect health and social care cost burden [17]. In 104 
addition, early diagnosis and intervention increases the quality of life and care planning for 105 
people with dementia and their caregivers, which promote independence [17]. In this context, 106 
it is clear that the potential economic and humane benefits of improving the clinical care 107 
pathway for dementia are immense. Indeed, as we shall discuss below, the application of 108 
data-driven computational approaches can have an immediate impact on improving dementia 109 
care pathway.  110 
 111 
Dementia care pathway  112 
 113 
To evaluate the effectiveness of dementia care, we must first assess the current dementia 114 
care pathway. As an example, the pre-eminent body in the UK working on clinical guidelines 115 
and standardised practices for medical professionals is the National Institute for Health and 116 
Care Excellence (NICE), with dementia care guidelines updated in 2018 to reflect current best 117 
practices [18]. The guidelines put forth several strong recommendations for how dementia 118 
care should be implemented at the primary care level, at specialist memory assessment 119 
services, and in the wider community. A schematic of the NICE 2018 recommendations for 120 
the dementia care pathway is illustrated in Fig. 1 [19]. Symptoms of dementia are usually first 121 
identified by either the individual themselves, a family member of caregiver, before being 122 
assessed by general practitioners (GPs). At the primary care level, a major focus is to exclude 123 
common and treatable causes of delirium or other disorders. If dementia remains a concern, 124 
further investigation and onward referral to secondary care is required, where more detailed 125 
assessment by a specialist (e.g. memory clinic) will diagnose dementia, and its subtype, and 126 
initiate treatment [20, 19].  127 
 128 
 129 
Fig. 1. Flowchart of the UK dementia care pathway under NICE guidelines, and potential 130 
disruption. Includes primary and secondary (specialist) care. Blue and purple text: potential 131 
time delays and under/misdiagnoses; and also opportunities for technologies and novel 132 
dementia markers. Flowchart based on [19].  133 
 134 
Two major issues that often impede the effectiveness of dementia care pathway are diagnoses 135 
and time delays (Fig. 1, blue and purple text). Regarding the former, the rates of dementia 136 
detection (underdiagnosis) can vary considerably [21] and the diagnosis of dementia, and its 137 
subtype, can be inaccurate [22, 23]. In one US study, depending on the permissiveness of 138 
clinical and neuropathological criteria, AD diagnosis sensitivity (true positive rate) can range 139 
between 71% to 97%, while it is between 44% to 71% for specificity (true negative rate) [24]. 140 
Suggested reasons for dementia misdiagnosis include physicians/GPs in primary care not 141 
being appropriately trained or confident in detecting the disease (within their brief consultation 142 
time), and lack of standardised validated screening protocols and/or routine implementation 143 
of screening [25, 22, 26].  144 
 145 
There is also a link between early diagnosis and dementia prevalence. It has been estimated 146 
that if early identification of risks and diagnosis, leading to proper treatments or interventions, 147 
can delay dementia onset by 2 years, the prevalence would reduce by 20%; with a further 148 
prevalence reduction of 50% if a delay of 5 years was achieved [27]. Interestingly, to decrease 149 
the national dementia underdiagnosis rate, the UK government has introduced the 150 
incentivisation for GPs dementia diagnosis (paid per case); unintended consequences of the 151 
approach include poor patient experience, false-positive diagnosis, and negative impacts on 152 
waiting lists in memory clinics due to increased numbers of referrals [28, 29, 30].  153 
 154 
Early and accurate diagnosis, on top of providing timely and appropriate care and treatment 155 
and reducing undue psychological stress associated with false positive diagnosis, also has 156 
economic benefits. In particular, past studies have shown that patients with prior AD 157 
misdiagnosis (false positive) used substantially more medical services until their (non-158 
comorbidity) vascular dementia diagnosis, leading to increased annual medical costs per 159 
patient; following corrected diagnosis, the medical costs converged to patients never 160 
diagnosed with AD [31, 32].  161 
 162 
Regarding the issue of delays in dementia diagnosis, this can be due to various factors. These 163 
include false negative diagnosis, caregivers’ lack of knowledge or reluctance to seek help, 164 
uncertainty from patients and families about when and where to seek help, poor 165 
communication and uncertainty from medical doctors [33, 22, 34]. For instance, in one review 166 
of services in England, waiting times for assessment can range from 3 to 184 days, while 167 
dementia diagnosis from referral could take up to 199 days [34]. Such delays could permit 168 
substantial cognitive decline. Further, patients identified with MCI have to wait for a follow-up 169 
re-evaluation in either a recommended 6-month time interval or when there is significant 170 
change in status [19].  171 
 172 
Assessments in dementia diagnosis  173 
 174 
To receive appropriate treatment and support, careful assessment for diagnosing dementia is 175 
necessary. Current assessments and their associated ‘markers’ for dementia can comprise 176 
several types, from clinical history, biological (e.g. blood- or brain-based) assessment, to 177 
neuropsychological and functional assessments (Table 1) [18]. Often, the choice of 178 
assessments is based on factors such as accuracy, sensitivity, specificity, cost effectiveness, 179 
and speed and convenience of use.  180 
 181 
Certain assessment types are more costly and less readily available than others. These 182 
include cerebrospinal fluid analysis and various neuroimaging modalities in secondary 183 
(specialist) care. Moreover, structural neuroimaging is recommended in all cases unless 184 
dementia is well advanced and dementia subtype is identified [18]. However, functional 185 
neuroimaging is conducted to diagnose dementia subtype even though some biomarkers such 186 
as beta-amyloid based PET, may have the ability to predict the risk of dementia several years 187 
prior to onset of dementia symptoms (albeit with low specificity) [35]. Thus, there is a need to 188 
strike a balance among reliable risk prediction, healthcare costs, and the inconvenience for 189 
the patient. In contrast, blood-based biomarkers have the potential to offer high-190 
throughput data and are easily subjected to repeated measurement even in frail, elderly 191 
people. Newer, e.g. neuroinflammatory based, markers may offer dementia risk prediction at 192 
even earlier pre-symptomatic period [14, 36], although the specificity to dementia, and hence 193 
practical use, remains unclear.  194 
 195 
Table 1. Summary of the UK’s primary and secondary (specialist) care diagnosis for people 196 
aged 40 years old and over with suspected diagnosis of dementia [18].  197 
Primary care diagnosis 
Diagnostic 
variables 
Potential diagnostic variables include: 
• Clinical history 
• Clinical cognitive assessment 
• Neuropsychological testing 
• Physical examination 
• Medication review 
 
Secondary (specialist) care diagnosis 
Diagnostic 
variables 
Potential diagnostic variables include: 
• Specified diagnostic criteria 
• Structural imaging (Magnetic Resonance Imaging (MRI) and Computed 
Tomography (CT)) 
• Single-photon emission computed tomography (SPECT) (e.g. blood flow, 
dopamine) 
• Positron emission tomography (PET) (e.g. fluorodeoxyglucose (FDG), amyloid) 
• Cerebrospinal fluid (CSF) examination 
• Electroencephalography (EEG) 
• Brain biopsy 
• Neuropsychological assessment 
• Functional assessment 
• Genetic testing 
• Neurological examination 
 198 
For cognitive, neuropsychological and functional assessments, some may require the 199 
presence of a clinician and nurse, and perhaps caregiver, while others may take a relatively 200 
long time to administer; a comprehensive investigation can even go beyond the timeframe of 201 
a medical appointment [19]. Thus, a balance between convenience and performance of such 202 
assessments are required. Interestingly, composite scales, which combine several 203 
neurocognitive subscales or with functional activity scales into a single summary score, have 204 
recently gathered high interest for preclinical, prodromal and mild AD, especially for early AD 205 
therapeutic research [37]. A composite test assesses different domains of cognition and 206 
function through the use of discrete subtests, and then averages the standard score means 207 
from these subsets to yield an overall score [38]. However, it remains unclear whether 208 
composites can actually perform better than the current battery of assessments.  209 
 210 
In terms of the health economics evidence for these assessments, a number of cost-utility 211 
analysis, which report on incremental costs and quality-adjusted life years (QALYs) analyses 212 
have been conducted [18]. For instance, [39] compared three cognitive and 213 
neuropsychological assessments often used by GPs (Mini-Mental State Examination (MMSE), 214 
general practitioner assessment of cognition (GPCOG), and 6-item cognitive impairment test 215 
(6CIT) and identified the most cost-effective option (GPCOG), while providing caution 216 
regarding the results’ sensitivity to dementia medicines. Similarly, a cost-utility analysis of 217 
(beta-amyloid based PET) neuroimaging markers by [40] supported its use in comparison to 218 
standard assessment alone or with cerebrospinal fluid (CSF) testing. However, these studies 219 
were often limited to a small number of assessments.  220 
 221 
Taken together, we have presented several current issues facing dementia assessments and 222 
care. In particular, we have emphasised that providing timely and accurate diagnosis is crucial 223 
within the dementia care pathway. To improve the effectiveness of dementia diagnosis and 224 
care, we shall discuss in the remainder of this review, the needs and challenges associated 225 
with clinical data transformation and computational approaches in both dementia research 226 
and in clinical practice. In particular, we shall emphasise the advantages of improving clinical 227 
data curation and integration, identifying new dementia markers and assessments through 228 
new fundamental sciences and algorithms, and the development of practical decision support 229 
systems. These will be discussed along with their challenges.  230 
 231 
Data digitisation, curation and integration  232 
 233 
To enable reliable data analyses for evidence-based solutions to improve dementia diagnosis 234 
and care, well curated and “clean” data are necessary. Compliance with some or all of the so-235 
called 5 C’s (clean, consistent, conformed, current, and comprehensive) of data quality [41] 236 
and appropriate data governance [42] is necessary. Although this is the case in most openly 237 
available dementia data acquired within the context of a research study, actual clinical or 238 
medical data paints a rather different picture.  239 
 240 
A major reason for “dirty” clinical data is due to the lack of standardisation in the dementia 241 
care pathway. For instance, in Northern Ireland, although data related to dementia could be 242 
formally retrieved and analysed (e.g. through the Health and Social Care Business Services 243 
Organisation’s Honest Broker Service), the set of dementia assessments adopted across 244 
different practice sites can differ. GPs in England also have similar non-standardisation in 245 
dementia assessments [43]. This could be due to the ambiguity within the national (NICE) 246 
guidelines, allowing diversity in approaches and locally based “best” practices. When these 247 
data are integrated, they can lead to heterogeneity in data variables and systematic missing 248 
(“dirty”) data [44, 45, 46]. Missing data could also likely arise from other conditions, such as 249 
certain individuals being more likely to complete surveys or respond well to questions, 250 
individuals late for medical appointments, and individuals with severe dementia unable to 251 
attend medical appointments altogether. Therefore, practical strategic approaches e.g. 252 
appropriate data cleaning, imputation and harmonisation techniques, are needed before 253 
conducting any analysis [47, 48, 49, 50, 51, 52]. Indeed, there are some recent and promising 254 
large-scale data extraction and integration initiatives such as the UK-CRIS (Clinical Record 255 
Interactive Search) system [53] (see below for more examples).  256 
 257 
An alternative solution to reduce heterogeneous data is to employ a “small data” approach. 258 
As discussed by [54] in this journal’s Collection, there are various advantages to this approach, 259 
which can uniquely manage complex, dynamic, multi-causal and complex diseases to facilitate 260 
individual-level description, prediction and control. Moreover, given the political, institutional 261 
and human-nature inertia to change, such localisation and decentralisation could actually be 262 
a more viable and economical approach, provided the localised data is of sufficient quality. 263 
Further, this approach may be suitable to handle known regional variation in the prevalence 264 
and detection of dementia associated with the age profile of the population and accessibility 265 
to services (e.g. see [7, 55] for examples in rural Ireland). Analytical results or models based 266 
on such data would also be localised, which may perhaps be more conducive for the practice 267 
of personalised or stratified medicine. If data linkages across regional data silos are 268 
implemented for analytical insights into wider patterns or trends, similar issues on data 269 
integration could arise, as discussed previously.  270 
 271 
Clinical or medical data may include unstructured or semi-structured data. For instance, 272 
transcription from handwritten notes from clinicians and nurses to consistent digital formats is 273 
needed before storing in operational data storage or data mart, and for use in analysis. With 274 
the advent of robust handwriting recognition algorithms, especially deep learning [56], this can 275 
be solved to some extent, but medical (e.g. International Classification of Diseases, ICD) 276 
codes may still need to be further decoded in an efficient way. Also, with increasing use of 277 
medical devices such as pervasive (wearable) sensors or detectors that generate continuous 278 
data stream and point-of-care technology, real-time signal processing and edge analytics, and 279 
other big data approaches would be needed [57, 58]. More fundamentally, the way clinical 280 
data is captured early on should be changed and formalised to allow better and systematic 281 
digitisation of electronic health or medical records. To enable this would require widespread 282 
adoption through policy change. Overall, setting a robust and practical data infrastructure is 283 
vital for any reliable data analytics or modelling.  284 
 285 
Computational Neurology, an integrative computational framework  286 
 287 
In [59], we introduced the umbrella term Computational Neurology to embrace not only 288 
Computational and Theoretical Neuroscience, which has largely focused on neural 289 
mechanistic or probabilistic modelling [60], but also data-driven artificial intelligence (AI) 290 
approaches to handle heterogeneous, complex and large data. Computational or Theoretical 291 
Neuroscience usually requires focused and relatively detailed data (e.g. across neighbouring 292 
spatial scales) to model, explain and predict specific biophysics of neural tissues, their 293 
activities and functions in either healthy or disordered brains, including in AD and dementia 294 
(see e.g. [59, 61-68] and references therein). Such causal based modelling approaches can 295 
help to test hypotheses and elucidate the mechanisms of brain disorders and potential 296 
therapeutics.  297 
 298 
For such approaches, the required detailed (biological) data may not always be readily 299 
available. Further, it may take a long time to realistically model or simulate large-scale brain 300 
activities for practical clinical purposes, although there are attempts using simpler reduced 301 
computational models [69-71]. Moreover, when data is heterogeneous or when biological 302 
information is lacking, biologically realistic mechanistic modelling to bridge across scales may 303 
not be feasible, and probabilistic or statistical modelling can be applied. Thus, with the 304 
unavailability of mechanistic systems models, causality may be inferred e.g. based on 305 
probabilistic models [60, 72, 73].  306 
 307 
When the data gets sufficiently large and complex, the applications of data mining, AI or 308 
machine learning become essential. This is especially the case for big data generated by new 309 
technologies, as discussed previously. Some of the wider perspectives on this topic have 310 
already been discussed in this journal’s Collection [74, 75]. Notable open big data initiatives 311 
include those for fundamental brain sciences such as the Allen Brain Map [76], Collation of 312 
Connectivity Data for the Macaque (CoCoMac) database [77], Human Connectome Project 313 
(HCP) [78], and for clinical and translational sciences, include the Cambridge Centre for 314 
Ageing Neuroscience (Cam-CAN) dataset inventory [79], Alzheimer’s Disease Neuroimaging 315 
Initiative (ADNI) [80], the National Alzheimer’s Coordinating Center (NACC) [81], UK Biobank 316 
[82], and the Dementias Platform UK (DPUK) [83]. Other large-scale projects include those 317 
coordinated by Innovative Medicines Initiative (IMI), e.g. the European Medical Information 318 
Framework (EMIF) [84], the European Prevention of Alzheimer’s Dementia Consortium 319 
(EPAD) [85], AETIONOMY (Organising mechanistic knowledge about neurodegenerative 320 
diseases for the improvement of drug development and therapy) [86], and Neuronet 321 
(Efficiently Networking European Neurodegeneration Research) [87].  322 
 323 
Importantly, these databases and platforms now enable researchers, particularly those with 324 
computational or theoretical inclination, to perform large-scale quantitative analyses to enable 325 
wider and more direct research impact (e.g. see [88]). There are also opportunities for 326 
researchers to link across mechanistic and data-driven computational approaches (e.g. see 327 
[89, 90]). Fig. 2 summarises the possible interactions of these various modelling approaches 328 
with different data types. Together, these computational approaches can be applied for deeper 329 
understanding of dementia, test potential therapeutics, and for detecting and predicting 330 




Fig. 2. Schematic of computational and theoretical approaches in Computational Neurology: 335 
from fundamental research towards clinical applications. Blue boxes: Small or focused data; 336 
brown: larger or more heterogeneous data. Arrows: Relationships. Sometimes artificial 337 
intelligence (AI), data mining and machine learning methods are also used in relatively smaller 338 
or less heterogeneous data to guide mechanistic modelling (not shown).  339 
 340 
Computationally derived and other novel markers of dementia  341 
 342 
Computational neurology applied to dementia can potentially solve some of the issues facing 343 
dementia diagnosis and prognosis. Particularly, data-driven models can provide more 344 
objective methods for detection and risk prediction of dementia. For some applications, the 345 
detection accuracy can be higher than that of humans. For instance, in the sub-area of 346 
computational neuroimaging, advanced techniques such as deep learning have led to very 347 
high accuracy for identifying dementia severity, outperforming human experts [91]. Some 348 
neuroimaging work, e.g. [92], has also combined multiple neuroimaging modalities to further 349 
enhance dementia predictive accuracy. However, to convince relevant stakeholders of their 350 
use in clinical practice, cost-utility analysis of these computational approaches and their 351 
identified markers may be needed.  352 
 353 
As compared to the current battery of dementia assessments, including recently suggested 354 
use of composite scales, computational researchers can now use algorithms to perform 355 
unbiased and automated selection of the most relevant assessments or variables, and their 356 
(optimal) combinations, for predicting dementia severity and risk (e.g. [73, 88]). Such data-357 
driven approaches may reveal markers that can lie beyond human intuition. Moreover, these 358 
computationally derived markers often consist of a smaller number of variables than standard 359 
assessments, while still able to provide reasonable (or higher) accurate prediction of 360 
dementia. Thus, there is potential that their use can lead to more effective dementia diagnosis.  361 
 362 
Novel biomarkers using newer technologies, not currently deployed in the dementia care 363 
pathway, may also have the potential to transform dementia diagnosis and prognosis. These 364 
include readily accessible novel blood-based markers (using high-throughput next-generation 365 
DNA sequencing, proteomic and metabolomic technologies) permitting identification of protein 366 
concentrations/activity/isoforms and post-translational modifications, metabolic products, 367 
such as amino acids, carbohydrates, lipids, organic acids, and nucleic acids (single nucleotide 368 
polymorphisms, SNPs) [93]. Similar data analytical, e.g. feature selection and dimensional 369 
reduction, methods can be used to home in and identify key markers [94, 95].  370 
 371 
Although not currently part of the dementia care pathway, magnetoencephalography (MEG), 372 
with its high temporal resolution, can more directly identify novel biomarkers for dementia and 373 
its prodromal stage. They can come in the form of abstract machine-learning or functional 374 
brain connectivity-based markers [96-99]. Given that electroencephalography (EEG), with 375 
poorer spatial localisation than MEG, has already been incorporated in dementia diagnosis 376 
(Table 1) [18], it may perhaps be not too inconceivable to also include MEG. Further, MEG, 377 
with its ease of use, may be more favourable for frail, elderly or demented participants owing 378 
to the avoidance of cumbersome procedures e.g. preparation of the electrodes and conducting 379 
gel as required for EEG. However, the current high costs associated with acquisition and 380 
maintenance of MEG instrumentation impede its widespread use.  381 
 382 
Post-clinical validation of computationally derived and other novel markers should be followed 383 
by discussion among policy makers, researchers and other stakeholders to allow their 384 
assimilation into the current dementia care pathway. For instance, in conjunction with the 385 
traditional set of assessments, assessment for novel blood-based markers could be performed 386 
using point-of-care technologies within primary care, while MEG assessment conducted at 387 
secondary care.  388 
 389 
Practical clinical decision support systems  390 
 391 
As of now, and in the foreseeable future, clinicians make an informed clinical diagnosis after 392 
weighing over all available diagnostic evidence. Given the complexity of the data forming such 393 
evidence and the decision-making processes required, computerised decision support 394 
systems (CDSSs) can act as tools to assist human experts with interpretation, diagnosis and 395 
treatment [100]. A CDSS may consist of a highly specialised computational model, e.g. for 396 
discriminating specific neuroimaging data [101]. It may also consist of systems based 397 
computational model that embraces a wide variety of data types or markers [102, 88]. 398 
Crucially, CDSS can act as a bridge from fundamental, data-driven research towards clinical 399 
application (Fig. 2).  400 
 401 
CDSSs can be useful to solve the underdiagnosis or misdiagnosis of dementia within primary 402 
care settings, thereby reducing the load at secondary care level. In fact, a criticism of the UK’s 403 
National Dementia Strategy has suggested that more diagnosis should take place in primary 404 
care [34]. Moreover, CDSSs can also provide more effective (e.g. neuroimaging) assessments 405 
within secondary care. Further, adoption of a common CDSS platform may promote more 406 
standardisation of dementia assessments. When incorporated into the telemedicine scene, 407 
the adoption of CDSS could be accelerated through awareness of its resolving of issues in 408 
financial costs, delays and accessibility (e.g. in an infectious disease pandemic) related to 409 
dementia diagnosis and care. In fact, with widespread use of smart phones, some dementia 410 
assessments may perhaps be digitised and conducted within the CDSS in mobile devices 411 
(e.g. the IMI RADAR-AD (Remote Assessment of Disease and Relapse – Alzheimer’s 412 
Disease) project [103], and the EDoN (Early Detection of Neurodegenerative diseases) project 413 
[104]), increasing accessibility to assessments, and expediting early diagnoses in cognitive 414 
decline and dementia and other supporting services [105-109]. However, this may also lead 415 
to potential data security and privacy issues [58].  416 
 417 
While developing computational models for CDSSs, care has to be taken as the models 418 
trained in e.g. open dementia datasets may consist of variables (e.g. specific cognitive 419 
assessments) that may not be the same as that in clinical practice. Also, individual cases are 420 
often not considered in analysis and model validation (but see e.g. [88]). In longitudinal studies 421 
for risk prediction, models need to take into account appropriate time trajectories [110] and 422 
trajectory heterogeneity [111]). Thus, many current models’ decisions may have inappropriate 423 
estimation of their predictive precisions for actual clinical practice. Moreover, in open dementia 424 
datasets the proportion of MCI or dementia individuals may not necessarily reflect the actual 425 
proportion in society. Thus, appropriate adjustment may be necessary before translational 426 
deployment. In addition, many computational modelling studies often struggle with obtaining 427 
high detection accuracy when dealing with MCI cases, regardless of the intrinsic strength of 428 
the models (e.g. [91]). This may be due to the studies failing to differentiate the subtypes of 429 
MCIs (e.g. amnestic MCI) or the ill-defined general term of MCI [112]. Fundamentally related 430 
to this is that the clinical classification of the disease is often mixed. We suggest that a next 431 
stage for dementia classification would arise from data-driven computational modelling rather 432 
than the standard labels in the Diagnostic and Statistical Manual of Mental Disorders (DSM-433 
5). Particularly, Computational Neurology could follow the path of Computational Psychiatry 434 
for mental health in the identification of disease categorisation and stages e.g. through data-435 
driven dimensional or network-based approaches [113, 114].  436 
 437 
Conclusion  438 
 439 
Currently, our understanding of dementia is lacking, and the dementia care pathway is 440 
suboptimal. We propose that Computational Neurology approaches can offer specific 441 
solutions. With mechanistic biologically based modelling, it can provide insights into underlying 442 
neural mechanisms and assist in dementia therapeutics research. Supported by appropriate 443 
data infrastructure, data-driven modelling and CDSS can provide immediate improvements 444 
through better dementia diagnosis and prognosis, and improve related care pathways, while 445 
potentially reducing delays and health and social care costs. New markers may be elucidated 446 
based on algorithms and new technologies, which may complement current diagnostic and 447 
prognostic processes.  448 
 449 
However, such benefits may only be realised if computational models and CDSSs are 450 
appropriately evaluated and adopted by users. Obstacles to implementation in clinical practice 451 
may be explained by general lack of engagement from clinicians, physicians and health 452 
specialists [115]. Indeed, many computational models of dementia may perhaps be too 453 
‘academic’ and lack translational characteristics. To move the field forward, it is imperative 454 
that computational researchers, informaticians, clinicians, patients, health institutions, policy 455 
makers, and other stakeholders should work synergistically together.  456 
 457 
 458 
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